Wei-Jie Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei-Jie Yuan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Nan Zhu
Department of Nephrology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
3 shared publications Xuan Wang
Department of Nephrology, Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, 100 Haining Road, Shanghai, 200080, China
3 shared publicationsYi Zhou
Shanghai Jiaotong University Affiliated Shanghai First People’s Hospital
3 shared publicationsLi-Jie Gu
Shanghai Jiaotong University Affiliated First People’s Hospital
2 shared publicationsLing Wang
Shanghai Jiaotong University Affiliated First People’s Hospital
2 shared publicationsZhou Yi
Department of Nephrology The First People's Hospital, Shanghai Jiaotong University, Shanghai, People's Republic of China
2 shared publications
Latest Publications
- 21 June 2013
- Published by Springer Nature in Archives of Virology
- Vol. 158 (12) , 2479-2485
Effects of hepatitis B virus X gene on apoptosis and expression of immune molecules of human proximal tubular epithelial cells
- 21 June 2013
- Published by Springer Nature in Archives of Virology
- Vol. 158 (12) , 2479-2485
Effects of hepatitis B virus X gene on apoptosis and expression of immune molecules of human proximal tubular epithelial cells
- 18 October 2012
- Published by Springer Nature in Archives of Virology
- Vol. 158 (2) , 425-433
The role of the toll-like receptor TLR4 in hepatitis B virus-associated glomerulonephritis
- 18 October 2012
- Published by Springer Nature in Archives of Virology
- Vol. 158 (2) , 425-433
The role of the toll-like receptor TLR4 in hepatitis B virus-associated glomerulonephritis
- Open Access
- 30 August 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (8) , e43655
Hemoglobin Targets for Chronic Kidney Disease Patients with Anemia: A Systematic Review and Meta-analysis
Numerous studies have identified a relationship between hemoglobin (Hb) levels and mortality in patients with chronic kidney disease (CKD), which have raised concerns about the optimal Hb targets in correction of anemia. Our study is designed to investigate the potential effects of targeted Hb levels, aiming to give some evidence for therapy of renal anemia. A comprehensive search of Medline, Embase and the Cochrane Database of Systematic Reviews was performed in December 2011 and updated in February 2012 for any new trials. Randomized trials designed to evaluate effects of high (generally the Hb about 13.0 g/dL) and low Hb (generally the Hb about 10.0 g/dL) targets on clinical outcomes in CKD patients with anemia were collected. All statistical analysis was calculated using the RevMan software available free from the Cochrane Collaboration. 24 trials involving 10361 patients were identified. Our findings demonstrated a statistically significant increased risk of mortality in the high Hb levels (RR 1.18; 95% CI 1.02 to 1.37) while the high and low Hb groups were both treated with ESAs. Overall, compared with low Hb levels, high Hb levels are associated with increased risk of hypertension (RR 1.40; 95% CI 1.11 to 1.75), stroke (RR 1.73; 95% CI 1.31 to 2.29), and hospitalizations (RR 1.07; 95% CI 1.01 to 1.14). However, there are no significant differences in the risk of non-fatal myocardial infarction (RR 1. 13; 95% CI 0.79 to 1.61) and renal replacement therapy (RR 1. 00; 95% CI 0.85 to 1.18). Targeting low Hb levels are beneficial to CKD patients especially in the predialysis population. The optimal Hb targets to aim for in CKD patients and at what Hb level the risks of adverse events begin to increase remain elusive. Future studies are still needed to elucidate these questions.
- 30 August 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (8) , e43655
Open AccessHemoglobin Targets for Chronic Kidney Disease Patients with Anemia: A Systematic Review and Meta-analysis
Numerous studies have identified a relationship between hemoglobin (Hb) levels and mortality in patients with chronic kidney disease (CKD), which have raised concerns about the optimal Hb targets in correction of anemia. Our study is designed to investigate the potential effects of targeted Hb levels, aiming to give some evidence for therapy of renal anemia. A comprehensive search of Medline, Embase and the Cochrane Database of Systematic Reviews was performed in December 2011 and updated in February 2012 for any new trials. Randomized trials designed to evaluate effects of high (generally the Hb about 13.0 g/dL) and low Hb (generally the Hb about 10.0 g/dL) targets on clinical outcomes in CKD patients with anemia were collected. All statistical analysis was calculated using the RevMan software available free from the Cochrane Collaboration. 24 trials involving 10361 patients were identified. Our findings demonstrated a statistically significant increased risk of mortality in the high Hb levels (RR 1.18; 95% CI 1.02 to 1.37) while the high and low Hb groups were both treated with ESAs. Overall, compared with low Hb levels, high Hb levels are associated with increased risk of hypertension (RR 1.40; 95% CI 1.11 to 1.75), stroke (RR 1.73; 95% CI 1.31 to 2.29), and hospitalizations (RR 1.07; 95% CI 1.01 to 1.14). However, there are no significant differences in the risk of non-fatal myocardial infarction (RR 1. 13; 95% CI 0.79 to 1.61) and renal replacement therapy (RR 1. 00; 95% CI 0.85 to 1.18). Targeting low Hb levels are beneficial to CKD patients especially in the predialysis population. The optimal Hb targets to aim for in CKD patients and at what Hb level the risks of adverse events begin to increase remain elusive. Future studies are still needed to elucidate these questions.
- 17 January 2012
- Published by Taylor & Francis in Renal Failure
- Vol. 34 (3) , 396-402
Timing of Initiation of Renal Replacement Therapy in Acute Kidney Injury: A Systematic Review and Meta-analysis
Objective: The aim of the study is to summarize the effects of timing of initiation of renal replacement therapy (RRT) on mortality. Methods: A systematic search for randomized controlled trials (RCTs) and other clinical studies was performed without language restriction in PubMed, Web of Science, and Embase. We estimated pooled relative risk ratios (RRs) and 95% confidence intervals (CIs) using fixed effects model or random effects model as appropriate. Heterogeneity, publication bias, and subgroup analyses were conducted. Results: We analyzed the date extracted from 15 studies (3 RCTs, 2 prospective, and 10 retrospective comparative cohort studies) with a total of 2955 patients. Overall, 51.0% (772/1514) patients died in the “early” RRT group compared with 58.0% (836/1441) in the “late” RRT group. The pooled RR was 0.71 (95% CI: 0.59, 0.86), but the heterogeneity existed (p < 0.00001). Subgroup analysis based on modality did not record heterogeneity across trials. In continuous RRT (CRRT) group (n = 607), patients treated with “early” CRRT suggested a significant decrease in mortality compared with those in “late” CRRT group (27.8% vs. 43.0%) and the RR was 0.69 (95% CI: 0.56, 0.84) without evidence of heterogeneity (I2 = 33%, p = 0.18). In intermittent hemodialysis (IHD) group (n = 115), the RR was 0.26 (95% CI: 0.15, 0.45) without evidence of heterogeneity (I2 = 0%, p = 0.50). In the mixed group, heterogeneity existed. Conclusion: “Early” CRRT and “early” IHD both could reduce the mortality of patients with acute kidney injury compared with “late” CRRT or IHD.
- 17 January 2012
- Published by Taylor & Francis in Renal Failure
- Vol. 34 (3) , 396-402
Timing of Initiation of Renal Replacement Therapy in Acute Kidney Injury: A Systematic Review and Meta-analysis
Objective: The aim of the study is to summarize the effects of timing of initiation of renal replacement therapy (RRT) on mortality. Methods: A systematic search for randomized controlled trials (RCTs) and other clinical studies was performed without language restriction in PubMed, Web of Science, and Embase. We estimated pooled relative risk ratios (RRs) and 95% confidence intervals (CIs) using fixed effects model or random effects model as appropriate. Heterogeneity, publication bias, and subgroup analyses were conducted. Results: We analyzed the date extracted from 15 studies (3 RCTs, 2 prospective, and 10 retrospective comparative cohort studies) with a total of 2955 patients. Overall, 51.0% (772/1514) patients died in the “early” RRT group compared with 58.0% (836/1441) in the “late” RRT group. The pooled RR was 0.71 (95% CI: 0.59, 0.86), but the heterogeneity existed (p < 0.00001). Subgroup analysis based on modality did not record heterogeneity across trials. In continuous RRT (CRRT) group (n = 607), patients treated with “early” CRRT suggested a significant decrease in mortality compared with those in “late” CRRT group (27.8% vs. 43.0%) and the RR was 0.69 (95% CI: 0.56, 0.84) without evidence of heterogeneity (I2 = 33%, p = 0.18). In intermittent hemodialysis (IHD) group (n = 115), the RR was 0.26 (95% CI: 0.15, 0.45) without evidence of heterogeneity (I2 = 0%, p = 0.50). In the mixed group, heterogeneity existed. Conclusion: “Early” CRRT and “early” IHD both could reduce the mortality of patients with acute kidney injury compared with “late” CRRT or IHD.
- Open Access
- 1 April 2011
- Published by Elsevier in Annals of Hepatology
- Vol. 10 (2) , 165-173
The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis
- 1 April 2011
- Published by Elsevier in Annals of Hepatology
- Vol. 10 (2) , 165-173
Open AccessThe efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis
- 26 March 2011
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 14 (2) , 125-132
High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients
High mobility group box protein-1 (HMGB-1) was recently identified as a new type of inflammatory cytokine. Inflammation can lead to malnutrition to some extent. Our study was aimed to clarify the relationship between serum HMGB-1 level with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis (CAPD) patients. Patients in the treatment of maintenance of peritoneal dialysis for >6 months were included. HMGB-1, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured by enzyme-linked immunosorbent assay (ELISA). High-sensitivity C-reactive-protein (hs-CRP), prealbumin (PA), serum albumin (S-Alb), hemoglobin (Hb), subjective global nutritional assessment (SGA), and CAPD presents’ urea clearance rate (Kt/V), creatinine clearance (CrCl), residual glomerular filtration rate (rGFR), and dialysate-to-plasma ratio of creatinine after 4 h (D/P4Cr) were analyzed. The Independent-samples t test and Pearson’s rank correlation test were used. Serum HMGB-1, IL-6, and TNF-α of CAPD patients were significantly higher than in the control group (P < 0.05); Serum HMGB-1 levels had positive relationships with TNF-α (r = 0.730, P < 0.01), hs-CRP (r = 0.361, P < 0.01), and IL-6 (r = 0.865, P < 0.01), and had negative relationships with Hb (r = −0.59, P < 0.01), Alb (r = −0.34, P < 0.05), and PA (r = −0.44, P < 0.01); no significant relationships were found between serum HMGB-1 with SGA, peritoneal dialysis age, Kt/V, CrCl, rGFR, and D/P4Cr. Our study revealed that HMGB-1 was elevated significantly in CAPD patients and correlated with indicators of inflammation and malnutrition. Serum HMGB-1 could be used as a marker for evaluating inflammation and malnutrition in CAPD patients.
- 26 March 2011
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 14 (2) , 125-132
High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients
High mobility group box protein-1 (HMGB-1) was recently identified as a new type of inflammatory cytokine. Inflammation can lead to malnutrition to some extent. Our study was aimed to clarify the relationship between serum HMGB-1 level with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis (CAPD) patients. Patients in the treatment of maintenance of peritoneal dialysis for >6 months were included. HMGB-1, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured by enzyme-linked immunosorbent assay (ELISA). High-sensitivity C-reactive-protein (hs-CRP), prealbumin (PA), serum albumin (S-Alb), hemoglobin (Hb), subjective global nutritional assessment (SGA), and CAPD presents’ urea clearance rate (Kt/V), creatinine clearance (CrCl), residual glomerular filtration rate (rGFR), and dialysate-to-plasma ratio of creatinine after 4 h (D/P4Cr) were analyzed. The Independent-samples t test and Pearson’s rank correlation test were used. Serum HMGB-1, IL-6, and TNF-α of CAPD patients were significantly higher than in the control group (P < 0.05); Serum HMGB-1 levels had positive relationships with TNF-α (r = 0.730, P < 0.01), hs-CRP (r = 0.361, P < 0.01), and IL-6 (r = 0.865, P < 0.01), and had negative relationships with Hb (r = −0.59, P < 0.01), Alb (r = −0.34, P < 0.05), and PA (r = −0.44, P < 0.01); no significant relationships were found between serum HMGB-1 with SGA, peritoneal dialysis age, Kt/V, CrCl, rGFR, and D/P4Cr. Our study revealed that HMGB-1 was elevated significantly in CAPD patients and correlated with indicators of inflammation and malnutrition. Serum HMGB-1 could be used as a marker for evaluating inflammation and malnutrition in CAPD patients.
- 25 December 2009
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 12 (4) , 242-246
Effects of genistein on secretion of extracellular matrix components and transforming growth factor beta in high-glucose-cultured rat mesangial cells
The ideal treatment for diabetic nephropathy should slow the progress of renal failure, delay the initiation of dialysis, and protect residual renal function in patients receiving dialysis. Renal mesangial cells play an important role in these processes. In the current study, we investigated the effects of genistein on rodent renal mesangial cells cultured in a high-glucose environment. Since overexpression of the extracellular matrix (ECM) components (type IV collagen and fibronectin) and transforming growth factor beta (TGF-β) have been previously implicated in the development of the renal glomerulus damage of diabetic nephropathy, we included these substances in our study. The results showed that high concentration of glucose (450 mg·dl−1) stimulated the synthesis of type IV collagen and fibronectin and the secretion of TGF-β. These responses were attenuated by genistein (≥5 μmol·l−1) in a dose- and time-dependent manner. In conclusion, we demonstrated that genistein could inhibit the secretion of ECM components and the expression of TGF-β at both the protein and mRNA levels. These findings should be followed up by further studies and clinical trials to verify the potential therapeutic effects of genistein on diabetic nephropathy.
- 25 December 2009
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 12 (4) , 242-246
Effects of genistein on secretion of extracellular matrix components and transforming growth factor beta in high-glucose-cultured rat mesangial cells
The ideal treatment for diabetic nephropathy should slow the progress of renal failure, delay the initiation of dialysis, and protect residual renal function in patients receiving dialysis. Renal mesangial cells play an important role in these processes. In the current study, we investigated the effects of genistein on rodent renal mesangial cells cultured in a high-glucose environment. Since overexpression of the extracellular matrix (ECM) components (type IV collagen and fibronectin) and transforming growth factor beta (TGF-β) have been previously implicated in the development of the renal glomerulus damage of diabetic nephropathy, we included these substances in our study. The results showed that high concentration of glucose (450 mg·dl−1) stimulated the synthesis of type IV collagen and fibronectin and the secretion of TGF-β. These responses were attenuated by genistein (≥5 μmol·l−1) in a dose- and time-dependent manner. In conclusion, we demonstrated that genistein could inhibit the secretion of ECM components and the expression of TGF-β at both the protein and mRNA levels. These findings should be followed up by further studies and clinical trials to verify the potential therapeutic effects of genistein on diabetic nephropathy.
- 1 November 2009
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 122 (22) , 2794-2797
Recurrence of primary hyperoxaluria after kidney transplantation: the report of two cases
- 1 November 2009
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 122 (22) , 2794-2797
Recurrence of primary hyperoxaluria after kidney transplantation: the report of two cases